



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



GYKI 52466 (hydrochloride)

Item No. 34418

CAS Registry No.: 192065-56-8
Formal Name: 4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine, monohydrochloride
MF: C₁₇H₁₅N₃O₂ • HCl
FW: 329.8
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GYKI 52466 (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the GYKI 52466 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. GYKI 52466 (hydrochloride) is soluble in the organic solvent methanol at a concentration of approximately 1 mg/ml.

Description

GYKI 52466 is an allosteric AMPA receptor antagonist.¹ It selectively inhibits AMPA-induced inward currents (IC₅₀ = 7.5 μM) over NMDA- or GABA-induced inward currents in primary rat hippocampal neurons at 50 μM but also inhibits kainate-induced inward currents in the same cells (IC₅₀ = 11 μM).² GYKI 52466 (10 μM) reduces the amplitude of spontaneous excitatory postsynaptic currents (EPSCs) in the same cells. It increases the latency to seizure onset and reduces mortality in a rat model of generalized tonic-clonic seizures induced by 4-aminopyridine (4-AP; Item No. 18511) when administered at doses of 25 and 50 mg/kg.¹ GYKI 52466 (30 mg/kg) prevents neuronal damage in the CA1 region of the hippocampus in a rat model of global ischemia-reperfusion injury induced by four-vessel occlusion.³

References

1. Weiczner, R., Krisztin-Péva, B., and Mihály, A. Blockade of AMPA-receptors attenuates 4-aminopyridine seizures, decreases the activation of inhibitory neurons but is ineffective against seizure-related astrocytic swelling. *Epilepsy Res.* **78(1)**, 22-32 (2008).
2. Donevan, S.D. and Rogawski, M.A. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. *Neuron* **10(1)**, 51-59 (1993).
3. Block, F., Schmitt, W., and Schwarz, M. Pretreatment but not posttreatment with GYKI 52466 reduces functional deficits and neuronal damage after global ischemia in rats. *J. Neurol. Sci.* **139(2)**, 167-172 (1996).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/04/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM